Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Biopharmaceuticals The vast majority of pharmaceutical products are compounds derived either from synthetic chemical processes, from naturally sources (plants, microorganisms), or combinations of both. Such compounds are used to regulate essential bodily functions or to combat disease-causing microorganisms. Limited quantities of some of these have historically been derived from organs of animals and from blood. Now genetic engineering helps to produce some of these molecules in unlimited quantities. In practice this involves inserting the necessary human-derived gene into suitable host microorganism that will further produce the therapeutic protein (biopharmaceutical) in quantities related to the scale of operation. The first human gene sequences encoding important therapeutic proteins, cloned into microorganisms, were insulin, human growth hormone (somatostatin) and the interferons. Thus, there are millions of people in the world who need regular intakes of insulin to overcome the lethal effects of diabetes. Insulin extracted from pigs and cattle has long been the source of worldwide usage, and some unfortunate side-effects have occurred due to additional contaminating compounds presented in the animal insulin. Recombinant human insulin has not such problems and now has the largest market share of sales. The growth hormone, somatostatin, has been extremely difficult to isolate from animals; half a million sheep brains were required to yield 0,005 g of pure somatostatin. By cloning the human gene for somatostatin into a bacterium, the same amount of hormone can be produced from 9 litres of a transgenic bacterial fermentation. One child of 5000 suffers from hypopituitary dwarfism resulting from growth hormone deficiency and easy availability of this biopharmaceutical will be of immense benefit to these child sufferers. The annual world market is estimated at $US 100 million. In 1957 two British researchers discovered substances produced within the body that could act against viruses by making cells resistant to virus attack. Most vertebrate animals can produce these substances, known as interferons, and many animal viruses can induce their in vitro synthesis and become sensitive to them. However, only small amounts of interferon are produced within cells, and it is very difficult to extract and separate them from other cellular proteins. Human interferons are glycoproteins (proteins with attached sugar molecules) and they control many types of viral infection, including cancer. They attack the cancer cells by inhibiting their growth, and they can also stimulate the body’s natural immune defences against the cancer cell. There are many different types of interferon characteristic of individual species of animals; mouse interferon will respond to mouse cells but not human cells, and vice versa. Furthermore, different tissues from the same species produce different interferons. Thus, interferon for human studies must be derived from human cells (primarily, using leukocytes from blood). Two sources of interferon are currently available. The first is from human diploid fibroblasts growing attached to a suitable surface. The second source is from bacteria in which the gene for human fibroblast interferon has been inserted into a plasmid in such a manner that interferon is synthesised and then extracted and purified. Lymphokines are proteins produced by lymphocytes (part of the body’s immune system) and are important to immune reactions. They have a capability of restoring the capacity of the immune system to fight infectious diseases or cancer. Interleukin-2 at present offers the greatest potential and is now produced by genetic engineering. At present, all biopharmaceuticals are produced by way of genetically engineered mammalian cell or microbial fermentations. However, with the development of transgenic animals (Chapter 10) it has become possible to produce certain human proteins of biopharmaceutical potential, including tissue plasminogen activator, blood clotting factors, etc. In the lactating glands of several animal species, such as mouse, cow and pig. These products can then be more easily extracted and purified. An American company can now produce human haemoglobin in the blood of transgenic pigs that could therefore serve as a human blood substitute. This transgenic haemoglobin is free from human pathogens such as HIV and it does not need matching before transfusion because it is not composed of red blood cells.